The key role of calreticulin in immunomodulation induced by chemotherapeutic agents

International Journal of Clinical Oncology

Volumn 20, Issue 2, 2015, Pages 386-394

  Yamamura, Yoshiyuki ^a   Tsuchikawa, Takahiro ^a   Miyauchi, Kengo ^a   Takeuchi, Shintaro ^a   Wada, Masataka ^a   Kuwatani, Toshihiko ^a   Kyogoku, Noriaki ^a   Kuroda, Aki ^a   Maki, Takehiro ^a   Shichinohe, Toshiaki ^a   Hirano, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calreticulin; Chemotherapy; HLA class I; Immunogenic cell death; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CAMPTOTHECIN; CD3 ANTIGEN; CISPLATIN; DEOXYCYTIDINE; FLUOROURACIL; GEMCITABINE; HLA ANTIGEN CLASS 1; MEMBRANE ANTIGEN; MITOMYCIN; MITOXANTRONE;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE COUNT; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PROTEIN TRANSPORT; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD3; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALRETICULIN; CAMPTOTHECIN; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOMODULATION; LYMPHOCYTE COUNT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOMYCIN; MITOXANTRONE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN TRANSPORT; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84934296030     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0719-x     Document Type: Article

References (22)

1. Marsh R de W, Alonzo M, Bajaj S et al (2012) Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management. J Surg Oncol 106:339–345
2. Weber GF, Rosenberg R, Murphy JE et al (2012) Multimodal treatment strategies for locally advanced rectal cancer. Expert Rev Anticancer Ther 12:481–494
3. Kageyama S, Kitano S, Hirayama M et al (2008) Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 99:601–607
4. Karbach J, Neumann A, Brand K et al (2012) Phase I clinical trial of mixed bacterial vaccine (Coley’s toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res 18:5449–5459
5. Tsuboi A, Oka Y, Kyo T et al (2012) Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 26:1410–1413
6. Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61
7. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160
8. Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109–126
9. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801–817
10. Galluzzi L, Senovilla L, Zitvogel L et al (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215–233
11. Berraondo P, Umansky V, Melero I (2012) Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res 72:5159–5164
12. Ma Y, Conforti R, Aymeric L et al (2011) How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 30:71–82
13. Cho Y, Miyamoto M, Kato K et al (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63:1555–1559
14. Hiraoka K, Miyamoto M, Cho Y et al (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275–280
15. Fukunaga A, Miyamoto M, Cho Y et al (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:26–31
16. Tsuchikawa T, Miyamoto M, Yamamura Y et al (2012) The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol 19:1713–1719
17. Tsuchikawa T, Hirano S, Tanaka E et al (2013) Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. Cancer Sci 104:531–535
18. Tanaka K, Tsuchikawa T, Miyamoto M et al (2012) Down-regulation of human leukocyte antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 40:965–974
19. Del Cid N, Jeffery E, Rizvi SM et al (2010) Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J Biol Chem 12:4520–4535
20. Raghavan M, Del Cid N, Rizvi SM et al (2008) MHC class I assembly: out and about. Trends Immunol 29:436–443
21. Rizvi SM, Del Cid N, Lybarger L et al (2011) Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules. J Immunol 186:2309–2320
22. Mimura K, Shiraishi K, Mueller A et al (2013) The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 191:6261–6272